4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kazia Therapeutics Limited (KZIA) operates in the Biotechnology industry and is headquartered in Sydney, Australia with about 6 employees. Its market capitalization is roughly $141 million. In the fiscal year ended 2025-06-30, KZIA reported AUD 0M in revenue and (AUD 21M) in net income.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
Interactive charts & full statements → Open the KZIA valuation workbench →
| Income statement | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Revenue | AUD 0M | AUD 2M | AUD 0M | AUD 0M |
| Operating Income (EBIT) | (AUD 14M) | (AUD 28M) | (AUD 24M) | (AUD 25M) |
| Net Income | (AUD 21M) | (AUD 27M) | (AUD 20M) | (AUD 25M) |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Assets | AUD 6M | AUD 22M | AUD 28M | AUD 36M |
| Total Liabilities | AUD 14M | AUD 32M | AUD 16M | AUD 18M |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KZIA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms